4 unchanged sentences
Amended and Restated Bylaws
−Removed: First Amendment to License Agreement dated April 16, 2021 between Cancer Research Technology Limited and Registrant
−Removed: First Amendment to Separation and Consulting Agreement dated May 21, 2021 between Registrant and Chase C.
−Removed: Employment Agreement dated June 8, 2021, between Registrant and Kevin Leon Cook
+Added: First Amendment to Separation and Consulting Agreement dated July 20, 2021, between Registrant and Brandi L.
+Added: Employment Agreement dated August 5, 2021, between Registrant and George A.
+Added: Lineage Cell Therapeutics, Inc.
+Added: 2021 Equity Incentive Plan,
+Added: Standard Form of Stock Option Grant Notice and Agreement for Employees and Consultants under the Lineage Cell Therapeutics, Inc.
+Added: 2021 Equity Incentive Plan
+Added: Form of Stock Option Grant Notice and Agreement for Non-Employee Directors under the Lineage Cell Therapeutics, Inc.
+Added: 2021 Equity Incentive Plan
+Added: Standard Form of Restricted Stock Unit Award Grant Notice and Agreement under the Lineage Cell Therapeutics, Inc.
+Added: 2021 Equity Incentive Plan
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
CELL THERAPEUTICS, INC.
+Added: November 10, 2021
Executive Officer
+Added: November 10, 2021
Kevin Leon Cook
−Removed: Chief Financial
+Added: Financial Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.